Showing results (2021-2030 of 4,519) with videos related to

Sort By:
Pageof 452
Advances in Therapy|September 27, 2018
Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing SurveillanceMeritxell Sabidó, Saritha Venkatesh, Brooke Hayward, et al.
Advances in Therapy|April 26, 2022
Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global CasesMohammed Al Dubayee, Meral Kayikcioglu, Jeanine Roeters van Lennep, et al.
Advances in Therapy|April 29, 2022
Iron Deficiency in Women's Health: New Insights into Diagnosis and TreatmentChristina M Moisidis-Tesch, Lee P Shulman
Advances in Therapy|April 29, 2022
Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in ChinaDunming Xiao, Yue Zhang, Wanxin Chen, et al.
Advances in Therapy|April 30, 2022
Improving Care in Eosinophil-Associated Diseases: A CharterDavid J Jackson, Praveen Akuthota, Rebeca Andradas, et al.
Advances in Therapy|October 12, 2021
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid ArthritisMartin Bergman, Namita Tundia, Min Yang, et al.
Advances in Therapy|October 30, 2021
Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database StudyYoshito Komatsu, Shuichi Hironaka, Yoshinori Tanizawa, et al.
Advances in Therapy|April 6, 2022
Treatment Patterns Among Patients with Bipolar Disorder in the United States: A Retrospective Claims Database AnalysisRakesh Jain, Amanda M Kong, Patrick Gillard, et al.
Advances in Therapy|April 8, 2022
Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness AnalysisYouwen Zhu, Kun Liu, Dong Ding, et al.
Advances in Therapy|May 3, 2022
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy SubgroupAnnabelle A Okada, Kanji Takahashi, Masahito Ohji, et al.
Pageof 452